Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
amyloid angiopathy, cerebral
antiarrhythmic drugs
anticoagulant, contraindications
anticoagulant, treatment
arrhythmia, cardiac
atrial appendage closure
atrial fibrillation
atrial fibrillation, surgical treatment
atrial fibrillation, treatment
cardiac surgery
cerebral embolism
cerebrovascular accident
cerebrovascular accident, cryptogenic
cerebrovascular accident, prevention of
cerebrovascular accident, secondary prevention
complications
controversies in neurology
cost effectiveness
coumarin
embolism, air
factor Xa inhibitor
intracerebral hemorrhage
intracerebral hemorrhage, familial
left atrial appendage
left atrial appendage, percutaneous closure
left atrium
non-vitamin K antagonist oral anticoagulants
pericardial effusion
peri-procedural
prevention of neurologic disorders
radiofrequency ablation
review article
risk factors
risk-benefit assessment
safety
treatment of neurologic disorder
Watchman device
Showing articles 0 to 50 of 1232 Next >>

Spontaneous Intracerebral Hemorrhage
NEJM 388:191-192, Vandertop,W.P.,et al, 2023

Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
NEJM 384:2081-2091,2154, Whitlock, R.P.,et al, 2021

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018

Managing Risk After Intracerebral Hemorrhage in Concomitant Atrial Fibrillation and Cerebral Amyloid Angiopathy
Stroke 47:e190-e192, Stoker, T.B.,et al, 2016

Left Atrial Appendage Function and Stroke Risk
Stroke 46:3554-3559, Yaghi, S.,et al, 2015

Percutaneous Left Atrial Appendage Closure:Technical Aspects and Prevention of Periprocedural Complications with the Watchman Device
Workd J Cardiol 26:65-75, Mobius-Winkler,S.,et al, 2015

A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011

Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009

Association of Atrial Septal Aneurysm and Shunt Size with Stroke Recurrence and Benefit From Patent Foramen Ovale Closure
JAMA Neurol 79:1175-1179, Mas,J-L.,et al, 2022

Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021

Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020

Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018

Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018

PFO Closure for Cryptogenic Stroke
NEJM 378:1639-1642, Mi, M.Y.,et al, 2018

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017

Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017

Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016

Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013

Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013

Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013

Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012

Critique of Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
Stroke 43:3147-3149, Thaler, D.E.,et al, 2012

Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012

Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010

Closure of Patent Foramen Ovale After Cryptogenic Stroke
Lancet 368:350-352, Wrle,J., 2006

Embolic Stroke Due to a Left Atrial Thrombus Two Years After Placement of an Atrial Septal Defect Closure Device
Am J Cardiol 98:1294-1296, Raghu,A.,et al, 2006

Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005

Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005

Practice Parameter: Recurrent Stroke with Patent Foramen Ovale and Atrial Septal Aneurysm
Neurol 62:1042-1050, Messe,S.R.,et al, 2004

Does Transcatheter Closure of Patent Foramen Ovale Really "Shut the Door?"
Stroek 35:2140, Anzola,G.P.,et al, 2004

Incidence and Clinical Course of Thrombus Formation on Atrial Septal Defect and Patent Foramen Ovale Closure Devices in 1,000 Consecutive Patients
J Am Coll Cardiol 43:302-309, Krumsdorf,U.,et al, 2004

Incidence of Thrombus Formation on the CardioSEAL and the Amplatzer Interatrial Closure Devices
Am J Cardiol 93:426-431, Anzai,H.,et al, 2004

Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004

Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004

Percutaneous Closure of Patent Foramen Ovale Reduces the Frequency of Migraine attacks
Neurol 62:1399-1401, Schwerzmann,M.,et al, 2004

Closure of a Patent Foramen Ovale is Associated with a Decrease in Prevalence of Migraine
Neurol 62:1439-1440, Post,M.C.,et al, 2004

Recurrent Thromboembolic Events After Percutaneous Device Closure of Patent Foramen Ovale
ICVTS 2:125-127, Brgermann,J.,et al, 2003

Prognosis After Percutaneous Closure of Patent Foramen Ovale for Paradoxical Embolism
Neurol 57:1330-1332, Wahl,A.,et al, 2001

Anticoagulation after Ablation for Atrial Fibrillation
NEJM 385:466-468, Kadire, S.R., 2021

Early Ablation for Paroxysmal Atrial Fibrillation - Safety First
NEJM 384:374-375, Marine, J.E., 2021

Neurologic Deterioration after Atrial Fibrillation Ablation
Neurol 95:e1766-e1767, Narrett, J.A.,et al, 2020

A 62-year-old man with history of catheter ablation presenting with recurrent strokes
Neurol 95:e3065-e3069, Jeanneret, V.,et al, 2020

Atrial Cardiopathy in Patients with Embolic Strokes of Unknown Source and Other Stroke Etiologies
Neurol 92:e288-e294, Jalini, S.,et al, 2019

Catheter Ablation for Atrial Fibrillation
JAMA 321:1255-1257, Albert, C.M.,et al, 2019

Neurologic Abnormalities After Atrial Fibrillation Ablative Procedure
JAMA Neurol 75:1144-1145, Stanton, R.J.,et al, 2018

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017

Selective Vulnerability of Cortical Border Zone to Microembolic Infarct
Stroke 46:1864-1869, Bergui, M.,et al, 2015

Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012

Catheter Ablation for Atrial Fibrillation
NEJM 365:2296-2304, Wazni, O.,et al, 2011



Showing articles 0 to 50 of 1232 Next >>